sotorasib
FDA Approves Lumakras With Vectibix for KRAS G12C–Mutated Colorectal Cancer
The FDA has approved sotorasib (Lumakras, Amgen) with panitumumab (Vectibix, Amgen) for adult patients with KRAS ...
JANUARY 21, 2025
New KRAS Inhibitor Improves PFS in NSCLC Harboring KRASG12C Mutation
A second drug has demonstrated efficacy against the once “undruggable” KRASG12C mutation. ...
JULY 18, 2022
FDA Approves First KRAS-Targeted Therapy, Lumakras, for NSCLC
The FDA granted accelerated approval to the RAS GTPase inhibitor sotorasib (Lumakras, Amgen) for the treatment of ...
JUNE 7, 2021
Load more